CYP2C19 and depressive symptom measurement: Figure 1 and Table S7 describe the association between the CYP2C19 and CYP2D6 phenotypes and the clinical outcomes in the individuals with depression who were using (es)citalopram, sertraline, or fluoxetine by the age groups.